Richard Gonzalez, AbbVie CEO (AP Images)

Ab­b­Vie chas­es its next gold­en goose in a post-Hu­mi­ra fu­ture with new ul­cer­a­tive col­i­tis da­ta for Rin­voq

Still bathing in the af­ter­glow of its big-mon­ey ac­qui­si­tion of Al­ler­gan, Ab­b­Vie faces the dark cloud of a post-Hu­mi­ra fu­ture — and the dead­line is ap­proach­ing fast. Key to Ab­b­Vie’s plan are two im­munol­o­gy launch­es with ag­gres­sive clin­i­cal dreams; one of those, JAK in­hibitor Rin­voq, is now one step clos­er to an­oth­er Hu­mi­ra-match­ing ap­proval.

Ab­b­Vie’s Rin­voq (upadac­i­tinib) best­ed place­bo in help­ing ul­cer­a­tive col­i­tis pa­tients achieve clin­i­cal re­mis­sion at the eight-week mark and sig­nif­i­cant­ly re­duced key symp­to­matic bio­mark­ers, in­clud­ing gas­troin­testi­nal in­flam­ma­tion, ac­cord­ing to da­ta from the Phase III U-Achieve study un­veiled Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.